BeOne Medicines (ONC) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for BeOne Medicines (NASDAQ: ONC):

• 7/14/2026 – BeOne Medicines had its price target lowered by Barclays PLC from $409.00 to $403.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $436.00 to $451.00. They now have an “outperform” rating on the stock.
• 7/7/2026 – BeOne Medicines had its price target raised by Truist Financial Corporation from $413.00 to $416.00. They now have a “buy” rating on the stock.
• 7/6/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/3/2026 – BeOne Medicines was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/1/2026 – BeOne Medicines had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $396.00 price target on the stock.
• 6/28/2026 – BeOne Medicines was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/20/2026 – BeOne Medicines was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/4/2026 – BeOne Medicines was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/2/2026 – BeOne Medicines had its price target raised by Royal Bank Of Canada from $425.00 to $436.00. They now have an “outperform” rating on the stock.
• 5/15/2026 – BeOne Medicines had its price target raised by Leerink Partners from $364.00 to $367.00. They now have an “outperform” rating on the stock.

Insider Activity at BeOne Medicines

In other news, CEO John Oyler sold 4,940 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40. Following the completion of the sale, the chief executive officer directly owned 1,120 shares in the company, valued at $303,027.20. This represents a 81.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lai Wang sold 1,367 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $269.38, for a total transaction of $368,242.46. Following the transaction, the insider owned 40 shares in the company, valued at $10,775.20. The trade was a 97.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 27,568 shares of company stock valued at $7,452,336. 6.19% of the stock is owned by insiders.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.